Summary
Agilent Technologies, Inc. announced a change in its Board of Directors composition on March 19, 2014. The Board size was expanded from 8 to 9 members with the appointment of Dr. George A. Scangos, effective September 17, 2014. Dr. Scangos, a seasoned executive with extensive experience in the biotechnology and pharmaceutical sectors, including his current role as CEO of Biogen Idec Inc., will serve on both the Compensation and Nominating/Corporate Governance Committees. His appointment is expected to bring valuable industry insights to the board.
Key Highlights
- 1Agilent Technologies appointed Dr. George A. Scangos to its Board of Directors.
- 2The Board size was increased from 8 to 9 members.
- 3Dr. Scangos' appointment is effective September 17, 2014.
- 4Dr. Scangos brings significant experience as CEO of Biogen Idec Inc. and prior leadership roles at Exelixis and Bayer Biotechnology.
- 5He will serve on the Compensation Committee and Nominating/Corporate Governance Committee.
- 6Dr. Scangos is considered an independent director and has no undisclosed arrangements or conflicts.
- 7His compensation will be standard for non-employee directors, prorated for the service period.
Frequently Asked Questions
Dr. George A. Scangos, aged 65, is a highly experienced executive in the biotechnology and pharmaceutical industry. He is currently the Chief Executive Officer and a director of Biogen Idec Inc. His prior experience includes serving as President and CEO of Exelixis, Inc., President of Bayer Biotechnology, and academic roles at Johns Hopkins University. He has also held board positions with Anadys Pharmaceuticals and chaired the California Healthcare Institute.
The Board of Directors increased its size from 8 to 9 members to accommodate the appointment of Dr. George A. Scangos. This expansion allows the company to bring in new expertise and perspectives to the board.
Dr. Scangos will serve as a director on the Board and will be a member of both the Compensation Committee and the Nominating/Corporate Governance Committee. He will receive the standard compensation paid to Agilent's non-employee directors, which will be prorated to reflect the portion of the year he serves on the Board in 2014.
The filing states that Dr. Scangos has no undisclosed arrangements or understandings regarding his appointment, no family relationships with company officers or directors, no material interest in any transactions with the company, and as of the filing date, no beneficial ownership of Agilent stock. The board has also determined he meets NYSE independence standards.